Skip to main content
SpringerLink
Log in

Age-related short-term effect of ramipril on N-terminal pro-brain natriuretic peptide and markers of hemostasis in patients after acute myocardial infarction

  • Original article
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Summary

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors after acute myocardial infarction (MI) prevent heart failure and recurrent ischemic events. Our aim was to evaluate the effect of ramipril on N-terminal pro-brain natriuretic peptide (NT-proBNP) and on markers of hemostasis, including plasminogen-activator-inhibitor-1 (PAI-1), von Willebrand factor (vWF), factor VIII (FVIII) and fibrinogen, in patients after acute MI, with emphasis on those over 55 years of age. METHODS: In this prospective, single-center, observational study 38 patients were treated with ramipril after the first Q-wave MI. Markers of hemostasis and NT-proBNP were estimated before and two weeks after ramipril treatment. RESULTS: Significant differences were observed in PAI-1 and NT-proBNP levels in patients over 55 years. In this age group the mean PAI-1 level decreased significantly after ramipril therapy (3.6 ± 1.25 U/ml vs. 2.65 ± 1.4 U/ml, P = 0.011) and was significantly lower than in younger (<55 years) patients (2.65 ± 1.4 U/ml vs. 4.39 ± 1.7 U/ml, P = 0.002). In addition, in the older patients the mean baseline NT-proBNP level was significantly higher than in the younger age group (258.35 ± 347.6 pmol/l vs. 17.1 ± 22 pmol/l, P = 0.028) and was also higher after ramipril therapy (240.5 ± 254.3 pmol/l vs. 67.3 ± 75.2 pmol/l, P = 0.034). In the younger patients, mean NT-proBNP after short-term ramipril therapy increased significantly in comparison with baseline (67.3 ± 75.2 pmol/l vs. 17.15 ± 22.0 pmol/l, P = 0.046). CONCLUSION: In acute Q-wave MI, increased PAI-1 levels, but not increased NT-proBNP, respond rapidly to early ACE inhibition by ramipril in patients over 55 years of age but not in younger patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Vaughan DE, Rouleau J-L, Ridker PM, Arnold MO, Menapace FJ, Pfeffer MA; on behalf of the HEART Study Investigators (1997) Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 96: 442–7

    CAS  PubMed  Google Scholar 

  • Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al (2004) Expert consensus document on angiotensin-converting enzyme inhibitors in cardiovascular disease. The task force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 25: 1454–70

    Article  PubMed  Google Scholar 

  • Boman KO, Jansson J-H, Nyhlen KA, Nilsson TK (2002) Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction. Throm Haemost 87: 311–6

    CAS  Google Scholar 

  • Shah AD, Arora RR (2005) Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors? Clin Cardiol 28: 551–5

    Article  PubMed  Google Scholar 

  • Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effect of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation Study Investigators. N Engl J Med 342: 145–53

    Article  CAS  PubMed  Google Scholar 

  • Fox KM; EURopean trial on reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA Study). Lancet 362: 782–8

    Article  CAS  PubMed  Google Scholar 

  • Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al (2002) N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106: 2913–8

    Article  CAS  PubMed  Google Scholar 

  • De Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe C, et al (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345: 1014–21

    Article  CAS  PubMed  Google Scholar 

  • Nordt TK, Peter K, Ruef J, Kübler W, Bode C (1999) Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 82[Suppl 1]: 14–8

    PubMed  Google Scholar 

  • Vaughan DE (2005) PAI-1 and atherothrombosis. J Thromb Haemost 3: 1879–83

    Article  CAS  PubMed  Google Scholar 

  • Agirbasli M (2005) Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 59: 102–106

    Article  CAS  PubMed  Google Scholar 

  • Trost S, Pratley R, Sobel B (2006) Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Curr Diab Rep 6: 47–54

    Article  CAS  PubMed  Google Scholar 

  • Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G (2005) Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 112: 3080–7

    Article  PubMed  Google Scholar 

  • Sinkovic A, Pogacar V (2004) Risk stratification in patients with unstable angina and/or non-ST-elevation myocardial infarction by Troponin T and plasminogen-activator-inhibitor-1 (PAI-1). Thromb Res 114: 251–7

    Article  CAS  PubMed  Google Scholar 

  • von Eyben FE, Mouritsen E, Holm J, Montvilas P, Dimcevski G, Suciu G, et al (2005) Plasminogen activator inhibitor 1 activity and other coronary risk factors. Clin Appl Thromb Hemost 11: 55–61

    Article  CAS  PubMed  Google Scholar 

  • Cooney MT, Dudina AL, O'Callaghan P, Graham IM (2007) von Willebrand factor in CHD and stroke: relationships and therapeutic implications. Curr Treat Options Cardiovasc Med 9: 180–90

    Article  PubMed  Google Scholar 

  • Matsukawa M, Kaikita K, Soejima K, Fuchigami S, Nakamura Y, Honda T, et al (2007) Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 100: 758–63

    Article  CAS  PubMed  Google Scholar 

  • Pilote L, Abrahamowicz M, Rodrigues E, Eisenberg MJ, Rahme E (2004) Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 141: 102–12

    PubMed  Google Scholar 

  • Tofler GH, Massaro J, Levy D, Mittleman M, Sutherland P, Lipinska I, et al (2005) Relation of the prothrombotic state to increasing age (from the Framingham Offspring Study). Am J Cardiol 96: 1280–3

    Article  PubMed  Google Scholar 

  • Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al (2003) Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society of cardiology. Eur Heart J 24: 28–66

    Article  PubMed  Google Scholar 

  • Hamsten A, Wiman B, de Faire U, Blomback M (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313: 1557–63

    CAS  PubMed  Google Scholar 

  • Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S (2006) Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368: 581–8

    Article  CAS  PubMed  Google Scholar 

  • Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355: 1575–81

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Intensive Care, University Medical Center Maribor, Maribor, Slovenia

    Andreja Sinkovič

  2. Faculty of Medicine, University of Maribor, Maribor, Slovenia

    Andreja Sinkovič

Authors
  1. Andreja Sinkovič
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreja Sinkovič.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sinkovič, A. Age-related short-term effect of ramipril on N-terminal pro-brain natriuretic peptide and markers of hemostasis in patients after acute myocardial infarction. Wien Klin Wochenschr 122 (Suppl 2), 74–78 (2010). https://doi.org/10.1007/s00508-010-1342-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-010-1342-0

Keywords

Search

Navigation